Response to COVID-19
Since the world first learned of a new coronavirus infection, HudsonAlpha Institute for Biotechnology Faculty Investigators and Associate Companies that call the biotech campus home have pivoted some of their efforts to battle the new invisible enemy, COVID-19.
The ability to quickly and accurately detect SARS-CoV-2, the virus that causes COVID-19 disease, is vitally important not only to treat, isolate, or hospitalize infected individuals but also to monitor and track how the virus is spreading within a community.
At the outset of the COVID-19 pandemic, companies residing on HudsonAlpha’s biotech campus increased laboratory testing capacity and launched point-of-care testing diagnostics.
While the ultimate tool for eradicating a new virus is a viral vaccine, vaccine development takes a lot of time. Developing treatments to reduce or alleviate symptoms of the virus is equally important on the road to eradicating SARS-CoV-2.
Several HudsonAlpha Faculty Investigators and Associate Companies on the biotech campus are working tirelessly to produce neutralizing monoclonal antibodies to treat COVID-19 disease symptoms by blocking its viral entry into our cells.
Why do some people get really sick and others don’t? Can we test a person’s blood and determine if they have been infected by or have immunity to SARS-CoV-2? These are the type of questions that HudsonAlpha Faculty Investigators and Associate Companies are trying to answer using their genetic sequencing expertise.
Through a project led by the Centers for Disease Control and Prevention, HudsonAlpha is also sequencing the viral genome from people who have been affected by the disease in an effort to monitor the spread and mutation of the virus.
Viral testing and contact tracing are important factors in determining the spread of SARS-CoV-2 in communities. However, our understanding of how the virus is transmitted and spread is still growing.
Projects studying the transmission of the virus through the air in enclosed areas, and the detection of dead viral particles in wastewater to monitor pending outbreaks in a community are among some of the environmental monitoring projects ongoing on HudsonAlpha’s campus.
The strength of HudsonAlpha lies in the culture of collaboration and a unique structure that encourages entrepreneurship. That strength is currently being demonstrated through the research and development of diagnostic and treatment tools to combat COVID-19. Companies among those on the HudsonAlpha campus working to combat this disease:
Partnered with multiple entities for outreach efforts in ethnic and racial minority communities disproportionately affected by COVID-19. Acclinate engaged and educated trial participants and biotech researchers to reduce underrepresentation and lead to better and safer medication.
Providing testing for COVID-19 with molecular testing panel that not only detects the virus that causes COVID-19, but also five bacterial pathogens associated with respiratory complications in high risk patients.
Continues to support the advancement of COVID-19 diagnostic testing and vaccine development by providing expert biospecimen solutions, genomic, immunohistochemistry and flow cytometry services.
Launched “Burl Gives Back” to address food insecurity due to the stay-at-home restrictions. The company is donating one bag of its Burl Barley Granola® product for every four bags of granola sold.
Foresight Biosciences has human cell-expressed both the receptor-binding domain (RBD) of the COVID-19 spike protein and angiotensin-converting enzyme 2 (ACE-2) for general research and commercial use.
Developed a technology that could collect the antibodies from patients who have recovered from COVID-19 and produce them in large quantities to then be used for treating patients with active disease.
Engineered a reagent critical to pathogen detection testing. This reagent was difficult to source during the early stages of the pandemic, limiting the number of tests available to the public. iXpressGenes worked quickly to optimize the manufacturing process to help diagnostic companies meet demand.
Developing affordable, non-invasive, routine screening of populations to identify infected individuals including those that are pre-symptomatic and asymptomatic to make workplaces and schools safer.
Operational Status as of : Operating under restricted campus access
HudsonAlpha is closely monitoring the ongoing Coronavirus Disease 2019 (COVID-19) outbreak. The health, safety, and well-being of our employees, associate companies and campus guests is our top priority. We have issued the following policies and recommendations regarding our employees, associate companies, visitors and program participants:
Use of Face Coverings on Campus
Anyone working on campus who is NOT fully vaccinated against COVID-19 is asked to wear a face mask when in close proximity (less than 6 feet) of others or in any public spaces (entering and exiting the building, conference rooms, hallways, coffee stations, restrooms, café, etc.)
Campus Visitor Policy
- Our buildings are closed to general public access
- All exterior doors of our campus buildings require badge access
- Visitors with a business need to be on campus need to contact an occupant directly for building access, and must be escorted at all times
- Hosts are responsible for screening visitors with the following criteria:
Remote Work Policy
All HudsonAlpha employees whose job duties permit, are required to work from home to the extent possible.
In cases when employees of HudsonAlpha or Associate Companies need to come to campus, additional steps to enhance social distancing, such as staggering shifts to reduce the number of employees present at a given time, are encouraged.
- Standard HudsonAlpha travel policies are in effect.
Employees are encouraged to follow current CDC guidance for travel safety.